Navigation Links
CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
Date:6/23/2008

1 million people in the United States have chronic angina, and 500,000 new cases are diagnosed annually, according to the American Heart Association.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. CV Therapeutics disclaims any
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
2. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
3. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
4. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
10. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
11. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Biopharmaceutical Industry Leads ... industry comes out on top as the country,s manufacturing ... new report  from ndp│analytics. According to the  analysis , ... investment over the last decade, accounting for 27 percent ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE and ... NexGen ® Complete Knee System. ... the 20 th year since Zimmer first introduced the NexGen ... market. To date, more than five million implantations of the NexGen ... history of the NexGen knee demonstrates the importance of design ...
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
Breaking Medicine Technology:Week in Review: The Latest from PhRMA 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... new product, RenalGuard®, at EuroPCR, the annual meeting of ... than 11,000 clinicians and medical professionals from around the ... take place in Paris, France from May 17-20, 2011. ...
... May 12, 2011 CVS Caremark was selected as ... for Best Practices in Health Care Consumer Empowerment and ... the finalists during URAC,s 12th Annual Quality Summit, October ... CVS Caremark,s Pharmacy Advisor program was selected ...
Cached Medicine Technology:PLC to Demonstrate RenalGuard® at EuroPCR 2011 2PLC to Demonstrate RenalGuard® at EuroPCR 2011 3CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 2CVS Caremark Named as Finalist for 2011 URAC Award for Best Practices in Health Care Consumer Empowerment and Protection 3
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
(Date:3/28/2015)... With more than 4,500 scientists, ... osteoporosis, osteoarthritis and musculoskeletal diseases gathered here for ... the first time in the 17-year history of ... hot-button topic is an emerging non-pharmaceutical protocol for ... principles of Wolff’s law, osteogenic loading at multiples ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... Chicago, IL (PRWEB) March 28, 2015 Centurion ... medical equipment auction on Thursday, April 2 at their Las ... Las Vegas, NV 89081. The sale, which consists of equipment ... will begin promptly at 9 a.m. PDT. , Buyers ... radiology and surgery equipment. “We are a one-stop-shop,” said Erik ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... PITTSBURGH, June 17 Mylan Inc. (Nasdaq: MYL ... received approval from the U.S. Food and Drug Administration (FDA) ... Capsules USP, 22.5 mg. This strength is in addition to ... the product. , , Temazepam Capsules are the generic ...
... Dad,s Personal Wellness ,Toolbox, Gets a Makeover with the Omron HEM-780 Blood ... Day, all eyes are on dad. From where to treat him ... role in the family and showing him how much we care. ... So this Father,s Day, rather than giving the usual cordless drill ...
... bankruptcy, and divorce skyrocket with the global recession, the people ... burden of these concerns can be agonizing, affecting both mental ... How to Defeat Stress Without Going Through the Embarrassment of ... of stress life can throw your way. Dr. Theu explains ...
... Footprint , , - Transaction Expected to be Accretive to ... - Enhances Watson,s Long Term Growth Profile , , MORRISTOWN, ... ) today announced that it has entered into a definitive agreement ... and stock. The combination of Watson and Arrow will result in ...
... , , , Oncology Test Further ... Calif., June 17 Cepheid (Nasdaq: CPHD ) today ... be marketed as a CE IVD product under the European Directive ... the test now detects the BCR-ABL chromosomal translocation in about 2 ...
... Group has revealed that despite the drooping economy Scots men ... in for moob removal surgery and finally getting their insecurities ... Transform Cosmetic Surgery Group has revealed that despite the ... this summer by booking in for moob removal surgery and ...
Cached Medicine News:Health News:This Father's Day Give Dad a Gift Straight for the Heart 2Health News:This Father's Day Give Dad a Gift Straight for the Heart 3Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 3Health News:Watson to Acquire Arrow Group 2Health News:Watson to Acquire Arrow Group 3Health News:Watson to Acquire Arrow Group 4Health News:Watson to Acquire Arrow Group 5Health News:Watson to Acquire Arrow Group 6Health News:Watson to Acquire Arrow Group 7Health News:Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) 2Health News:Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) 3Health News:Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML) 4Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 2Health News:Scots Men Get the Issue of Moobs Off Their Chests in Time for Summer - Male Surgery in Scotland Sees 80 Per Cent Growth 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: